Viewing nowSaisin Tablet 500 mg (Ciprofloxacin Hydrochloride)
Ciprofloxacin Hydrochloride 582mg
Tablet · Prescription medication
Il Dong Pharmaceutical Co., Ltd.

MFDS item code 199000363 · Notified 1990.05.12 · Insurance code 642900910
Treatment of genitourinary infections, respiratory and ear, nose, and throat infections, and other infections (such as skin and eye infections)
This medication is used for the treatment of infections caused by various bacteria. It is particularly effective for respiratory infections excluding acute bronchitis and pneumonia occurring in the community. It can also be used for infections ranging from ear, nose, and throat infections to bacterial prostatitis, acute cystitis, acute pyelonephritis, and urinary tract infections. The medication is suitable for treating infections in various sites, including gonococcal cervicitis and urethritis, gastrointestinal infections, biliary tract infections, skin and soft tissue infections, and infections of bones and joints. It is also intended for treating gynecological infections, peritonitis, fistulas, and styes. However, it should be used cautiously for some mild infections only when no other treatment options are available, and serious adverse reactions should be monitored. This medication is effectively used for the treatment of infectious diseases.
(Tablets 250, 500 mg) ○ The usual adult dose is 250~500 mg of ciprofloxacin per dose, administered orally twice daily between meals. For severe complicated infections, the dose may be increased to 750 mg per dose twice daily. For acute infections, treatment is usually given for 5~10 days, and continued for at least 3 days after symptoms have disappeared. ○ Patients with renal impairment 1) Creatinine clearance > 50 mL/min: Administer the usual dose 2) 30~50 mL/mn: Administer 250~500 mg per dose twice daily 3) 5~29mL/min: Administer 250~500 mg every 18 hours 4) Patients receiving hemodialysis or peritoneal dialysis: Administer 1 dose of 250~500 mg once daily after dialysis 5) If only the serum creatinine level is known, creatinine clearance can be calculated using the following formula. Men: {body weight(kg) × (140-age)}/ {72 × serum creatinine(mg/dL)} Women: 0.85 × the value calculated for men 6) For severe infections, the dose per administration may be increased to 750 mg even in patients with severe renal impairment; however, the patient's condition should be carefully monitored after administration. Adjust the dose appropriately according to age and symptoms. (Extended-release tablets 500 mg) 1. Uncomplicated urinary tract infection (acute cystitis): Administer 500 mg of this drug orally once daily for 3 days. 2. Complicated urinary tract infection, acute pyelonephritis: Administer 1,000 mg of this drug orally once daily for 7∼14 days. 3. Patients with renal impairment 1) No dosage adjustment is necessary if creatinine clearance is greater than 30 mL per minute or serum creatinine is 1.9 mg/100 mL or less. 2) If creatinine clearance is 30 mL per minute or less or serum creatinine is 2.0 mg/100 mL or greater, the maximum daily dose should be limited to 500 mg of this drug. 4. No dosage adjustment is necessary in patients with cirrhosis who have stable chronic cirrhosis. (Extended-release tablets 1,000 mg) 1. Administer 1,000 mg of this drug orally once daily for 7~14 days. 2. Patients with renal impairment 1) No dosage adjustment is necessary if creatinine clearance is greater than 30 mL per minute or serum creatinine is 1.9mg/100 mL or less. 2) If creatinine clearance is 30 mL per minute or less or serum creatinine is 2.0 mg/100 mL or greater, the maximum daily dose should be limited to 500 mg of the extended-release tablet. 3. No dosage adjustment is necessary in patients with cirrhosis who have stable chronic cirrhosis. (Injection) 1. Dose 1) The usual adult dose is 100∼400 mg of ciprofloxacin per dose, administered twice daily. 2) For mild or moderate urinary tract infections, administer 200 mg of ciprofloxacin per dose twice daily; for severe or complicated urinary tract infections, increase the dose to 400 mg of this drug per dose twice daily. 3) For mild or moderate lower respiratory tract infections, skin or skin structure infections, and bone and joint infections, administer 400 mg of this drug per dose twice daily. 2. Duration of administration: The average duration of treatment with this drug for injection is usually 7~14 days; for bone or joint infections, it should be administered for 4~6 weeks or longer. Administration should usually be continued for an additional 2 days after the symptoms of infection have disappeared. 3. Administer this drug by intravenous infusion over 60 minutes or longer. The dose should be determined taking into consideration the severity of each patient's infection, the susceptibility of the causative organism, the patient's condition, and hepatic and renal function. After initial intravenous treatment, the patient may be switched to an oral formulation according to the patient's condition. 4. Patients with renal impairment 1) Creatinine clearance ≥ 30 mL/min: Administer the usual dose 2) 5~29 mL/min: Administer 200~400 mg every 18~24 hours 3) If only the serum creatinine level is known, creatinine clearance can be calculated using the following formula. Men: {body weight(kg) × (140-age)}/ {72 × serum creatinine(mg/dL)} Women: 0.85 × the value calculated for men
This medication is a fluoroquinolone antibiotic used for the treatment of certain bacterial infections. However, serious side effects such as tendonitis or tendon rupture, peripheral neuropathy, and central nervous system abnormalities can occur, so caution is needed. In particular, individuals with myasthenia gravis should not take this drug as symptoms may worsen. This medication is only to be used for limited infections such as acute bacterial rhinosinusitis, acute exacerbations of chronic bronchitis or chronic obstructive pulmonary disease, uncomplicated urinary tract infections, and acute otitis media. Elderly patients, patients with impaired renal function, those with a history of seizures, and individuals with central nervous system disorders should be more cautious when taking this medication and consult with a physician if necessary. Furthermore, pregnant women, women who may become pregnant, nursing mothers, adolescents under 18, individuals with epilepsy, and those who have had hypersensitivity reactions to this medication or other quinolone antibiotics should not take this drug. This medication has many drug interactions, particularly with theophylline, tizanidine, ketoprofen, warfarin, and diabetes medications, and must be discussed with a physician or pharmacist before use. If symptoms such as tendon pain or inflammation, sensory abnormalities, mental changes, seizures, severe diarrhea, skin rash, or jaundice occur during treatment, treatment must be discontinued immediately and medical advice sought. This medication can increase sensitivity to sunlight, so strong sunlight or ultraviolet exposure should be avoided, and appropriate protective measures should be taken if necessary. For the elderly, since renal function may be decreased leading to prolonged retention of the drug in the body, dosage adjustment may be required, and caution is also needed for patients with aortic aneurysm or valvular heart disease. In the case of overdose, kidney damage may occur, so it is essential to strictly adhere to the prescribed dosage. Lastly, this medication is not recommended for children and growing adolescents; it should be stored out of reach of children and protected from direct sunlight.
Tendinitis, tendon rupture, peripheral neuropathy, central nervous system effects, exacerbation of myasthenia gravis, fungal superinfection, antibiotic-associated colitis, eosinophilia, thrombotic venous inflammation, leukopenia, anemia, neutropenia, leukocytosis, thrombocytopenia, thrombocytosis, erythrocytopenia, hemoglobin reduction, decreased hematocrit, granulocytopenia, leukolysis, hemolytic anemia, agranulocytosis, pancytopenia, bone marrow suppression, increased INR value, syndrome of inappropriate antidiuretic hormone secretion, allergic reaction, allergic edema, angioedema, anaphylactic reaction, anaphylactoid shock, serum sickness-like reaction, decreased appetite, reduced food intake, increased serum alkaline phosphatase, hyperglycemia, hypoglycemia, increased lipase, abnormal prothrombin levels, increased amylase, psychomotor agitation, anxiety, confusion, disorientation, emotional instability, abnormal dreams, depression, hallucinations, psychotic reactions, toxic psychosis, headache, dizziness, sleep disorders, taste disorders, insomnia, sensory abnormalities, sensory loss, loss of taste, tremor, convulsions, vertigo, mental confusion, seizures, drowsiness, migraine, coordination impairment, olfactory disorders, anosmia, sensory hypersensitivity, increased intracranial pressure, ataxia, peripheral neuropathy, polyneuropathy, visual impairment, color vision disturbance, diplopia, tinnitus, hearing loss, transient hearing impairment, hearing damage, tachycardia, vasodilation, hypotension, syncope, vasculitis, QT prolongation, ventricular arrhythmia, Torsades de Pointes, dyspnea, laryngeal edema, nausea, diarrhea, loss of appetite, gastric discomfort, vomiting, gastrointestinal and abdominal pain, abdominal distension, dyspepsia, pseudomembranous colitis, hematochezia, stomatitis, oral candidiasis, gastrointestinal candidiasis, pancreatitis, liver function abnormalities, increased bilirubin, liver dysfunction, jaundice, hepatitis, cholestatic jaundice, hepatic necrosis, rash, itching, urticaria, photosensitivity, vesicles, petechiae, erythema multiforme, drug reaction with eosinophilia and systemic symptoms, fixed drug eruption, acute generalized exanthematous pustulosis, arthralgia, musculoskeletal pain, myalgia, arthritis, increased muscle tone and cramps, joint swelling, muscle weakness, partial or complete tendon rupture, renal impairment, increased serum creatinine, acute renal failure, hematuria, crystalluria, interstitial nephritis, vaginal candidiasis, undetermined pain, discomfort, fever, asthenia, edema, sweating, gait disturbances, maculopapular rash, purpuric rash, aortic aneurysm, aortic dissection, cardiac valve regurgitation, cardiac valve insufficiency, shock, hypotension, feeling of chest tightness, muscle weakness, rhabdomyolysis, cough, abnormal chest X-ray findings, eosinophilia, interstitial pneumonia, visual impairment
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air ingress and kept at room temperature between 1°C and 30°C. Proper storage helps maintain the drug's efficacy and prevent degradation.
White oval-shaped film-coated tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCiprofloxacin Hydrochloride 582mg
Tablet · Prescription medication
Il Dong Pharmaceutical Co., Ltd.

Ciprofloxacin Hydrochloride 291.5mg
Tablet · Prescription medication
HK inno.N Co., Ltd.
Ciprofloxacin Hydrochloride
Prescription medication
Dongkwang Pharmaceutical Co., Ltd.

Ciprofloxacin Hydrochloride 291mg
Tablet · Prescription medication
Il Dong Pharmaceutical Co., Ltd.

Ciprofloxacin Hydrochloride Hydrate 291mg
Tablet · Prescription medication
Korea United Pharm, Inc.
Ciprofloxacin Hydrochloride Hydrate 291mg
Tablet · Prescription medication
SK Chemicals Co., Ltd.

Ciprofloxacin Hydrochloride Hydrate 291mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.

Ciprofloxacin Hydrochloride Hydrate 291mg
Tablet · Prescription medication
SS Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.